Incretin therapy may benefit patients with diabetes and STEMI

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Incretin therapy may be optimal for patients with type 2 diabetes (T2D) and ST elevation myocardial infarction-multivessel nonobstructive coronary stenosis (STEMI-Mv-NOCS).

Why this matters

  • Few data guide management of patients with T2D with STEMI-Mv-NOCS.

Study design

  • Prospective study of 1061 consecutive patients with first STEMI-Mv-NOCS (20%-49% luminal stenosis) undergoing coronary angiography.
  • Of 292 with diabetes, 122 used incretins (26 used glucagon-like peptide-1 receptor agonist and 96 dipeptidyl peptidase-4 inhibitor; mean treatment duration, 27 months).
  • 67 incretin users matched to 67 nonusers.
  • Primary endpoint: all-cause and cardiac deaths, and major adverse cardiac events (MACEs) at 12 months.
  • Funding: RicercaAteneo fund.

Key results

  • All-cause deaths at 1 year in 2.2% patients with diabetes vs 1.1% without (P=.05), and cardiac deaths in 1.6% vs 0.5%, respectively (P=.045).
  • MACE in 12.9% with diabetes vs 5.9% without (P<.01>
  • In the diabetes group, MACE occurred in 7.4% of incretin users vs 12.9% of nonusers (P=.04).
  • In risk-adjusted analysis, the diabetes group had approximately doubled risks for all-cause deaths (HR, 2.172; P=.01), cardiac deaths (HR, 2.253; P=.007), and MACE (HR, 1.962; P=.018).
  • Incretin therapy had no effect on all-cause or cardiac deaths, but MACE was significantly reduced (HR, 0.565; P=.003).

Limitations

  • Small sample size.
  • Short follow-up.